# A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants

> **NCT07737717** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **ModernaTX, Inc.** · enrollment: 84 (actual)

## Conditions studied

- Ebola-Bundibugyo Virus Disease (Ebola-BDBV)

## Interventions

- **BIOLOGICAL:** mRNA-1469
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT07737717
- **Lead sponsor:** ModernaTX, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2026-07-31
- **Primary completion:** 2027-09-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07737717

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07737717, "A Study to Investigate the Safety, Reactogenicity, and Immunogenicity of mRNA-1469 Vaccine to Prevent Ebola-Bundibugyo Virus Disease in Healthy Adult Participants". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07737717. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*